Literature DB >> 27146815

Clinical significance of ADAMTS1, ADAMTS5, ADAMTS9 aggrecanases and IL-17A, IL-23, IL-33 cytokines in polycystic ovary syndrome.

M Karakose1, K Demircan2, E Tutal3, T Demirci3, M S Arslan3, M Sahin4, H T Celik5, F Kazanci5, J Karakaya6, E Cakal3, T Delibasi3.   

Abstract

PURPOSE: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. A disintegrin and metalloproteinase with thrombospondin-like motifs (ADAMTS) are involved in inflammation and fertility. The aim of this investigation was to evaluate the serum levels of ADAMTS1, ADAMTS5, ADAMTS9, IL-17, IL-23, IL-33 and to find out the relationship between these inflammatory cytokines and ADAMTSs in PCOS patients.
METHODS: A case-control study was performed in a training and research hospital. Eighty patients with PCOS and seventy-eight healthy female volunteers were recruited in the present study. Serum ADAMTS and IL levels were determined by a human enzyme-linked immunoassay (ELISA) in all subjects.
RESULTS: The IL-17A, IL-23 and IL-33 levels were significantly higher in the PCOS patients compared to the controls (p < 0.05). We could not find significant difference between the groups in terms of ADAMTS1, ADAMTS5 and ADAMTS9 levels. IL-17A had positive correlations with LDL cholesterol and IL-33 and negative correlations with ADAMTS1, ADAMTS5, and ADAMTS9. IL-33 had positive correlation with LDL cholesterol and IL-17A. In ROC curve analysis, PCOS can be predicted by the use of IL-17A, IL-23 and IL-33 which at a cut-off value of 8.37 pg/mL (44 % sensitivity, 83 % specificity), 26.75 pg/mL (36 % sensitivity, 64 % specificity) and 14.28 pg/mL (83 % sensitivity, 39 % specificity), respectively.
CONCLUSIONS: The results of the study might suggest that ADAMTS and IL molecules have a role in the pathogenesis of the PCOS. Further efforts are needed to establish causality for ADAMTS-IL axis.

Entities:  

Keywords:  ADAMTS; Insulin resistance; Interleukin; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2016        PMID: 27146815     DOI: 10.1007/s40618-016-0472-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  44 in total

Review 1.  A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms.

Authors:  Suneel S Apte
Journal:  J Biol Chem       Date:  2009-09-04       Impact factor: 5.157

Review 2.  A new biological marker candidate in female reproductive system diseases: Matrix metalloproteinase with thrombospondin motifs (ADAMTS).

Authors:  Kadir Demircan; İsmail Cömertoğlu; Sümeyya Akyol; Beyza Nur Yiğitoğlu; Esma Sarıkaya
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-12-01

3.  Regulated expression of ADAMTS family members in follicles and cumulus oocyte complexes: evidence for specific and redundant patterns during ovulation.

Authors:  JoAnne S Richards; Immaculada Hernandez-Gonzalez; Ignacio Gonzalez-Robayna; Eva Teuling; Yuet Lo; Derek Boerboom; Allison E Falender; Kari H Doyle; Richard G LeBaron; Vivian Thompson; John D Sandy
Journal:  Biol Reprod       Date:  2005-01-19       Impact factor: 4.285

4.  Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease.

Authors:  Andrew J Krentz; Denise von Mühlen; Elizabeth Barrett-Connor
Journal:  Menopause       Date:  2007 Mar-Apr       Impact factor: 2.953

Review 5.  Ovulation: new factors that prepare the oocyte for fertilization.

Authors:  Joanne S Richards
Journal:  Mol Cell Endocrinol       Date:  2005-04-29       Impact factor: 4.102

6.  Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance.

Authors:  Andrea D Coviello; Richard S Legro; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2005-10-25       Impact factor: 5.958

7.  Systematic analysis of protease gene expression in the rhesus macaque ovulatory follicle: metalloproteinase involvement in follicle rupture.

Authors:  Marina C Peluffo; Melinda J Murphy; Serena Talcott Baughman; Richard L Stouffer; Jon D Hennebold
Journal:  Endocrinology       Date:  2011-07-26       Impact factor: 4.736

Review 8.  Interleukin-23: a key cytokine in inflammatory diseases.

Authors:  Emilie Duvallet; Luca Semerano; Eric Assier; Géraldine Falgarone; Marie-Christophe Boissier
Journal:  Ann Med       Date:  2011-05-17       Impact factor: 4.709

9.  Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity.

Authors:  Héctor F Escobar-Morreale; José I Botella-Carretero; Gemma Villuendas; José Sancho; José L San Millán
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

10.  IL-23 gene expression in PBMCs of patients with coronary artery disease.

Authors:  Maryam Khojasteh-Fard; Milad Abolhalaj; Parvin Amiri; Majid Zaki; Zahra Taheri; Mostafa Qorbani; Javad Tavakkoly Bazzaz; Mahsa M Amoli
Journal:  Dis Markers       Date:  2012       Impact factor: 3.434

View more
  14 in total

1.  Matrix-degrading protease ADAMTS-5 cleaves inter-α-inhibitor and releases active heavy chain 2 in synovial fluids from arthritic patients.

Authors:  Carsten Scavenius; Emil Christian Poulsen; Ida B Thøgersen; Margaret Roebuck; Simon Frostick; George Bou-Gharios; Kazuhiro Yamamoto; Bent Deleuran; Jan J Enghild
Journal:  J Biol Chem       Date:  2019-09-04       Impact factor: 5.157

2.  Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.

Authors:  Subeka Abraham Gnanadass; Yogamaya Divakar Prabhu; Abilash Valsala Gopalakrishnan
Journal:  Arch Gynecol Obstet       Date:  2021-01-13       Impact factor: 2.344

Review 3.  Is cardiorespiratory fitness impaired in PCOS women? A review of the literature.

Authors:  S Donà; E Bacchi; P Moghetti
Journal:  J Endocrinol Invest       Date:  2016-12-27       Impact factor: 4.256

Review 4.  The immune system's role in PCOS.

Authors:  Maryam Shamsi; Ali Ghazavi; Amir Mohammad Saeedifar; Ghasem Mosayebi; Sana Khajeh Pour; Ali Ganji
Journal:  Mol Biol Rep       Date:  2022-06-25       Impact factor: 2.316

5.  The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.

Authors:  S Jafari-Sfidvajani; R Ahangari; M Hozoori; H Mozaffari-Khosravi; H Fallahzadeh; A Nadjarzadeh
Journal:  J Endocrinol Invest       Date:  2017-11-06       Impact factor: 4.256

6.  Low-Dose Tacrolimus Prevents Dysregulated Peri-Conceptional Ovarian and Systemic Immune Cellular Homeostasis in Subjects with PCOS.

Authors:  Ahmad J H Albaghdadi; Carolyn Ann Feeley; Frederick W K Kan
Journal:  Sci Rep       Date:  2019-04-25       Impact factor: 4.379

7.  The Role of Chronic Inflammation in Polycystic Ovarian Syndrome-A Systematic Review and Meta-Analysis.

Authors:  Shaimaa Aboeldalyl; Cathryn James; Emaduldin Seyam; Emad Moussa Ibrahim; Hossam El-Din Shawki; Saad Amer
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

8.  Reduced Angiopoietin-2 as a Predictive Biomarker for Clomiphene Citrate Resistance in Polycystic Ovary Syndrome.

Authors:  Luxmipratha Rajendiran; Hanumanthappa Nandeesha; Thyagaraju Chitra
Journal:  J Hum Reprod Sci       Date:  2021-06-28

9.  ADAMTS1 and HSPG2 mRNA levels in cumulus cells are related to human oocyte quality and controlled ovarian hyperstimulation outcomes.

Authors:  Yerong Ma; Jiamin Jin; Xiaomei Tong; Weijie Yang; Peipei Ren; Yongdong Dai; Yibin Pan; YinLi Zhang; Songying Zhang
Journal:  J Assist Reprod Genet       Date:  2020-01-23       Impact factor: 3.412

10.  PCOS without hyperandrogenism is associated with higher plasma Trimethylamine N-oxide levels.

Authors:  Jiayu Huang; Lin Liu; Chunyan Chen; Ying Gao
Journal:  BMC Endocr Disord       Date:  2020-01-06       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.